A Randomized Trial of Angiotensin Receptor bLocker,Fimasartan, in Aortic Stenosis (ALFA Trial)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT01589380

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01589380
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01589380. Randomized; quadruple masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2013-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Randomized Trial of Angiotensin Receptor bLocker,Fimasartan, in Aortic Stenosis (ALFA Trial)
Acronym
ALFA
Condition
Critical Stenosis of Aortic Valve
Intervention (Drug)
Fimasartan
Intervention (Drug)
Placebo
Lead sponsor
Seoul National University Hospital (class: other)
Collaborator
Boryung Pharmaceutical Co., Ltd (class: industry)
Collaborator
Seoul National University Bundang Hospital (class: other)
Collaborator
Severance Hospital (class: other)
Collaborator
Korea University Anam Hospital (class: other)
Collaborator
Korea University Guro Hospital (class: other)
Collaborator
Chonnam National University Hospital (class: other)
Collaborator
Samsung Medical Center (class: other)

Record details

Record id
cardio:ct-nct01589380
Content hash
4823df27f502bead399d9a70529326e2c34021192b6c144c9fd6dc72ed0be747